Giving Credit Where Credit Is Due

As the few people who come up to my site already realize, I’ve had a strained relationship a good amount of the time with my editors at Seeking Alpha.  Quite frankly, I’m a difficult person to work with because I have impossible standards for myself that bleeds over to unrealistic expectations of others.

Yesterday, however, Mike Taylor, Eli Hoffman, George Moriarty, Daniel Shvartsman and company did something truly heroic.  They allowed me to speak openly within a published piece on Seeking Alpha about an added layer of due diligence I perform on most stocks I consider called a tarot card reading.  This is no small thing.  Many, if not most, people treat practitioners of tarot as if they were charlatans.  Just as marginalizing are those who feign acceptance while insisting we not talk about it thereby keeping it in the closet.

Therefore, I wish to thank Mike, Eli, George, Daniel and anyone else who participated in that decision for their courage.  I doubt seriously that anyone of them has an experience with this craft that would afford them the confidence in it that I possess, but that’s what makes their choice uncommon, and what makes me highly appreciative.

And I want to thank Mike Taylor, once again, for saving me due embarrassment by nixing the publication of my naïve submission on NovaBay recently.  Due because I haven’t learned to stop falling for the nonsense that biotech executives habitually throw out there for gullible people like me to eat up.  In this regard, and many others, I’m a total loser.  Mike saved me from myself.  And for that I’m grateful.

Always be well…

Michael Webb

Astellas To Acquire Ocata Therapeutics

Japanese biotech Astellas is set to acquire Ocata Therapeutics at a 90% premium to the previous day’s closing price.  This is yet another Scrying Biotech triumph joining Trevena, Amarin and Synergy Pharmaceutical as plus 100% hits in 2015, the latter of which climbed 298% since my initial coverage earlier in the year.  While controversial to many long-term holders of the equity, Ocata represents the latest example of a well-timed trade.  Here’s my September 5th Tweet…

Twitter on Ocata

If someone is having a better year blogging or investing in biotech, please let me know who they are by emailing me at:  I’ll leave you with my latest TipRanks profile capture.  And let you know that Zafgen (ZFGN) will continue to climb, albeit, in spurts as the company makes its scientific and clinical pursuits whole again.

TipRanks 11-11-15

Always be well…